Carl L Whatley

US Patent:

20100010029, Jan 14, 2010

Filed:

May 2, 2007

Appl. No.:

12/298922

Inventors:

William R. Maichle - Lowell NC, US
Carl L. Whatley - Montgomery AL, US
Giorgio Reiner - Como, IT
Alberto Reiner - Como, IT

Assignee:

Kowa Phamaceuticals America, Inc. - Montgomery AL
APR Applied Pharma Research, S.A. - Balerna

International Classification:

A61K 31/4355
A61K 31/445
A61K 31/34
A61K 31/196

US Classification:

514282, 514315, 514468, 514567

Abstract:

Provided are combined oral dosage forms for the treatment of pain, particularly combined dosage forms that are specially formulated for rapid bioavailability, and that contain diclofenac potassium and an opioid selected from hydrocodone, oxycodone, fentanyl and tramadol.

US Patent:

20100016363, Jan 21, 2010

Filed:

Apr 25, 2007

Appl. No.:

12/298550

Inventors:

William R. Maichle - Lowell NC, US
Carl L. Whatley - Montgomery AL, US
Giorgio Reiner - Como, IT
Alberto Reiner - Como, IT

Assignee:

Kowa Pharmaceuticals America, Inc. - Montgomery AL
APR Applied Pharma Research, S.A. - Balerna

International Classification:

A61K 31/454
A61K 31/196
A61K 31/4045
A61K 31/4196
A61K 31/422
A61K 31/405
A61P 25/22

US Classification:

514323, 514567, 514415, 514383, 514376

Abstract:

Therapeutic regimens and dosage forms are disclosed for the treatment of migraine headache. The regimens preferably combine a serotonin receptor agonist, such as sumatriptan, eletriptan or almotriptan, with a fast acting formulation of diclofenac potassium.

US Patent:

20070184106, Aug 9, 2007

Filed:

Feb 7, 2006

Appl. No.:

11/348634

Inventors:

Norman Schellenger - Midlothian VA, US
William Maichle - Lowell NC, US
Carl Whatley - Montgomery AL, US
Giorgio Reiner - Como, IT
Alberto Reiner - Como, IT

International Classification:

A61K 9/20
A61K 31/195

US Classification:

424464000, 514563000

Abstract:

Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.